Patents Assigned to MEIRAGTX UK II LIMITED
  • Patent number: 11739333
    Abstract: The present disclosure provides polynucleotide constructs for the modulation of target gene expression by aptamer-mediated ribonuclease cleavage of the target gene RNA and methods of using the constructs to modulate gene expression in response to the presence or absence of a ligand that binds the aptamer. The polynucleotide constructs contains a ribonuclease substrate sequence (e.g., an RNase P substrate) and a riboswitch comprising an effector region and an aptamer such that when the aptamer binds a ligand, target gene expression occurs.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 29, 2023
    Assignee: MEIRAGTX UK II LIMITED
    Inventor: Xuecui Guo
  • Patent number: 11697815
    Abstract: The invention provides polynucleotide constructs for the regulation of gene expression by aptamer-based modulation of U1 small nuclear ribonucleoprotein (snRNP)-mediated suppression of polyadenylation and methods of using the constructs to regulate gene expression in response to the presence or absence of a ligand that binds the aptamer. The polynucleotide construct contains a U1 binding site in the context of a riboswitch comprising an effector region and an aptamer such that when the aptamer binds a ligand, target gene expression occurs.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 11, 2023
    Assignee: MEIRAGTX UK II LIMITED
    Inventors: Michael J. Volles, Olivier F. Danos, Xuecui Guo
  • Publication number: 20230021959
    Abstract: The present disclosure relates to methods and compositions for elevating and stabilizing retromer for treating and/or preventing Alzheimer's disease and other neurodegenerative disorders. Additionally, the disclosure relates to adenoviral based therapy for treating Alzheimer's disease (AD), and other neurodegenerative conditions such as Parkinson's Disease (PD), neuronal ceroid lipofuscinosis (NCL), and transmissible spongiform encephalopathies (TSEs or prion disease), multiple system atrophy (MSA), Down's syndrome, and hereditary spastic paraplegia, as well as tauopathies such as progressive supranuclear palsy (PSP), frontotemporal lobar dementia linked to chromosome 17q21-22 and its subtypes (FTLD-17/FTLD-Tau), Lewy Body Disease (LBD), amyotrophic lateral sclerosis (ALS), frontal-temporal degeneration (FTD), ALS-FTD, and chronic traumatic encephalopathy (CTE).
    Type: Application
    Filed: December 7, 2020
    Publication date: January 26, 2023
    Applicants: The Trustees of Columbia University in the City of New York, Cornell University, Meiragtx UK II Limited
    Inventors: Scott A. SMALL, Gregory PETSKO, Rebecca COX, Samuel D. WAKSAL, Alexandria FORBES, Yasir H. QURESHI
  • Patent number: 11512310
    Abstract: The invention provides polynucleotide constructs for the regulation of gene expression by aptamer-based modulation of self-cleaving ribozymes and methods of using the constructs to regulate gene expression in response to the presence or absence of a ligand that binds the aptamer. The invention further provides methods for making and using riboswitches that decrease target gene expression in response to an aptamer ligand as well as riboswitches that increase target gene expression in response to an aptamer ligand.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: November 29, 2022
    Assignee: MEIRAGTX UK II LIMITED
    Inventors: Michael J. Volles, Olivier F. Danos, Alex R. Boyne, Veronique Zennou, Xuecui Guo
  • Patent number: 11371077
    Abstract: The invention provides eukaryotic cell-based screening methods to identify an aptamer that specifically binds a ligand, or a ligand that specifically binds an aptamer, using a polynucleotide cassette for the regulation of the expression of a reporter gene where the polynucleotide cassette contains a riboswitch in the context of a 5? intron-alternative exon-3? intron. The riboswitch comprises an effector region and an aptamer such that when the aptamer binds a ligand, reporter gene expression occurs.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: June 28, 2022
    Assignee: MEIRAGTX UK II LIMITED
    Inventors: Xuecui Guo, Alexandria Forbes, Lei Feng
  • Patent number: 11248239
    Abstract: The invention provides a platform and methods of using the platform for the regulation of the expression of a target gene using exposure to an aptamer ligand (for example, a small molecule). The platform features a polynucleotide gene regulation cassette that is placed in the target gene and includes a synthetic riboswitch positioned in the context of a 5? intron-alternative exon-3? intron. The riboswitch comprises an effector region and a sensor region (e.g., an aptamer that binds a small molecule ligand) such that the alternative exon is spliced into the target gene mRNA when the ligand is not present thereby preventing expression of the target gene. When the ligand is present, the alternative exon is not spliced into the target gene mRNA thereby providing expression of the target gene.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 15, 2022
    Assignee: MEIRAGTX UK II LIMITED
    Inventors: Alex R. Boyne, Olivier F. Danos, Michael J. Volles, Xuecui Guo
  • Publication number: 20200239940
    Abstract: The invention provides eukaryotic cell-based screening methods to identify an aptamer that specifically binds a ligand, or a ligand that specifically binds an aptamer, using a polynucleotide cassette for the regulation of the expression of a reporter gene where the polynucleotide cassette contains a riboswitch in the context of a 5? intron-alternative exon-3? intron. The riboswitch comprises an effector region and an aptamer such that when the aptamer binds a ligand, reporter gene expression occurs.
    Type: Application
    Filed: August 3, 2017
    Publication date: July 30, 2020
    Applicant: MeiraGTx UK II Limited
    Inventors: Xuecui Guo, Alexandria Forbes, Lei Feng
  • Patent number: 10494646
    Abstract: The invention provides a platform and methods of using the platform for the regulation of the expression of a target gene using exposure to an aptamer ligand (for example, a small molecule). The platform features a polynucleotide gene regulation cassette that is placed in the target gene and includes a synthetic riboswitch positioned in the context of a 5? intron-alternative exon-3? intron. The riboswitch comprises an effector region and a sensor region (e.g., an aptamer that binds a small molecule ligand) such that the alternative exon is spliced into the target gene mRNA when the ligand is not present thereby preventing expression of the target gene. When the ligand is present, the alternative exon is not spliced into the target gene mRNA thereby providing expression of the target gene.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: December 3, 2019
    Assignee: MEIRAGTX UK II LIMITED
    Inventors: Alex R. Boyne, Olivier F. Danos, Michael J. Volles, Xuecui Guo